Home
Health Education
Related Links

BREAST CANCER SCREENING
Maria Minerva P. Calimag, MD

Breast Masses

>Screening Program >Evaluation of breast masses in women >Self Breast Examination >Differential diagnosis of breast masses >Carcinoma of the breast >Treatment options >Prognosis

About 178,000 new cases of breast cancer and 43,000 deaths in 1999 and one out of every 8 or 9 women will develop breast cancer during their lifetime. Early detection definitely leads to better prognosis.

Screening options include (1) Breast self-examination; (2) Physical examination; and (3) Mammography

BREAST SELF EXAMINATION. Breast self-examination should be done by all women over age 20 every month. The best time is 5-7 days after menstruation. The breasts should be inspected in front of the mirror with the hands at the sides, overhead, and pressed on the hips to contract pectoralis muscles. In supine position, place a pillow under the right shoulder and right hand under the head. Using the three middle fingers of the left hand palpate the entire breast in circular, up and down line or wedge pattern. Repeat the same sequence on the left side with fingers of right hand. Repeat the examination of both breasts while standing, with one arm behind the head. It is harmless, inexpensive and may be beneficial.
BREAST SELF-EXAMINATION
The breasts should be inspected in front
of the mirror with the hands overhead...
hands on the side and pressed on
the hips to contract pectoralis
muscles...
In supine position, place a pillow
under the right shoulder and
right hand under the head..
Using the three middle fingers of the
left hand palpate the entire breast...
in circular...
in wedge pattern...
or in up and down line.

PHYSICAL EXAMINATION. About 40% of early breast cancers can be discovered physical examination. Change in size, shape, contour ,color of the skin and nipple discharge should be noticed. Palpation of the breast done with the patient seated and supine is done. Palpation of supraclavicular and axillary area should also be the part of physical examination.
PHYSICAL EXAMINATION
Inspection of the breast done with the patient
seated and supine is done....
In supine position palpate the breast
starting from the outer quadrants...
then the inner quadrants of the breast...
Palpation of supraclavicular and axillary
area should also be the part of physical
examination...
Change in size, ...
Change in shape and contour, ...
Change in color and consistency of the skin, ...
and nipple discharge should be noted. ...

MAMMOGRAPHY. About 35-50% of early breast cancers can be discovered by mammography Slowly growing breast cancers can be identified at least 2 years before clinically palpable. Two methods commonly in use: (1) Ordinary film radiography (less radiation exposure; (2) Xeroradiography. V- or Y-shaped clusters of calcifications vs. mass density with or without calcification are identified. Mammographic findings should be correlated with physical examination.

WHEN TO SCREEN. National Cancer Advisory Board (March 1997) and the American Cancer Society proposes that screening be done every 1-2 years for women in their 40s with average risk and women with high risk should seek expert medical advice on when to begin screening. Screen every year for asymptomatic women starting at age 40 and screen every year for all the women > 50 years old. Efficacy of screening in women above 70 years of age is controversial.

OTHER SCREENING OPTIONS. (1) Ultrasonography; (2) Biopsy, which can include Fine-needle aspiration cytology, Large-needle biopsy, Open biopsy. Other imaging modalities include (1) Ductography, (2) Diaphanography, (3)Thermography. Cytology of the nipple discharge should be done

DIFFERENTIAL DIAGNOSIS: (1) Mammary Dysplasia (Fibrocystic Disease; (2) Fibroadenoma of the breast; (3) Cystosarcoma phyllodes; (4) Lipoma; (5) Breast abscess; (6) Fat necrosis; (7) Galactocele; (8) Carcinoma of the breast.

MAMMARY DYSPLASIA. Painful, often multiple, usually bilateral masses. Rapid fluctuation in size is common. Frequently, increase in pain and size of the masses is noted in the premenstrual phase. Most common age is 30-50 years old. It is rare in post-menopausal women not receiving hormonal replacement. Aspiration of fluctuant masses may be needed for symptomatic treatment of pain and to rule out malignancy.

Sometimes, biopsy is needed to confirm the diagnosis Supportive treatment: (a) Good breast support; (b)Eliminate caffeine consumption; (c) Vitamin E 400 IU QD; (d) Danazol 100-200 mg BID for severe pain. The risk of breast cancer is higher in these women. These women should be followed periodically by physical examination and mammography.

FIBROADENOMA. It is the most common benign neoplasm. It usually occurs within 20 years after puberty.It does not normally occurs after menopause except in women on hormonal replacement. Typical tumor is round, rubbery, discrete, relatively movable, nontender mass 1-5cm in size. Sometimes, excision biopsy under local anesthesia is needed to confirm the diagnosis.

CYSTOSARCOMA PHYLLOIDES. Fibroadenoma-like tumor with cellular stroma that tends to grow rapidly. It may reach a large size and if inadequately excised will recur locally. The lesion is rarely malignant. In general, complete removal of the tumor should avoid recurrence. Simple mastectomy is sometimes needed to achieve complete control.

BREAST ABSCESS. During nursing, an area of redness, tenderness and induration not infrequently develops in the breast. Most commonly associated organism is S.Aureus. In the earlier stages, infection can often be controlled by oral antibiotics, dicloxacillin or oxacillin 250mg QID. You may continue nursing. If the lesion progresses to form a mass, abscess should be drained and nursing discontinued.

FAT NECROSIS. Rare lesion but often produces mass often accompanied by skin or nipple retraction. Trauma is presumed to be the cause. Tenderness may or may not be present. If untreated, the mass gradually disappears. As a rule, excision biopsy should be done to rule out malignancy.

BREAST CANCER. RISK FACTORS include:

(a) White race
(b) Increased age
(c) Family history in mother, sister or daughter
(d) BRCA1 or BRCA2 mutation
(e) Previous history of endometrial cancer, some forms of mammary dysplasia and cancer in the other breast
(f) Early menarche or late menopause
(g) Nulliparous or late first pregnancy

TREATMENT OF BREAST CANCER Curative-1990 NIH consensus statement asserts that breast-conserving surgery followed by radiation is the preferred treatment for early-stage breast cancer. Recommended for stage I , II, some cases of stage III (locally advanced) and even inflammatory tumors.
Curative interventions include (1) Lumpectomy alone; (2) Lumpectomy followed by radiation; (3) Radical Mastectomy and (4) Modified radical mastectomy.

Palliative -Some cases of stage III; All cases of Stage IV; Previously treated patients who develop distant metastasis or have unresectable local cancers.
Palliative interventions include (1) Radiotherapy; (2) Hormone Therapy; and (3) Chemotherapy.

RADIOTHERAPHY. Locally advance cancers with distant metastases. Treatment of certain bone or soft tissue metastases to control pain or avoid fracture Irradiation of the breast and chest wall and the axillary, internal mammary and supraclavicular nodes should be undertaken.

HORMONE THERAPY. In estrogen receptor positive tumors, response rate is about 60%. Response rate could be as high as 80% if tumor is progesterone receptor positive as well. Forms of hormone therapy: (a) Estrogens and antiestrogens; (b) Androgens; (c) Progestins; (d) Ablation of ovaries, adrenals or pituitary.

CHEMOTHERAPY. Cytotoxic drugs should be considered for the treatment of metastatic breast cancer; if visceral metastasis is present; when hormone treatment unsuccessful, if the tumor is ER-negative. Various regimens available, are (a) CMF, (b) AC, (c) PAF, (d) Paclitaxel and Docetaxel.

ADJUVANT CHEMOTHERAPY FOR PREMENOPAUSAL WOMEN

Nodal Involvement Estrogen Receptor Adjuvant Therapy


Yes

Positive Combination Chemotherapy


Yes

Negative Combination Chemotherapy


No

Positive Tamoxifen


No

Negative Combination Chemotherapy

ADJUVANT CHEMOTHERAPY FOR POSMENOPAUSAL WOMEN

Nodal Involvement Estrogen Receptor Adjuvant Therapy


Yes

Positive Tamoxifen


Yes

Negative Combination Chemotherapy


No

Positive Tamoxifen


No

Negative Combination Chemotherapy

FOLLOW-UP CARE. After primary therapy, patients should be followed for life, to detect recurrences; to observe the opposite breast for a second primary. During the first 3 years, patient is examined every 3-4 months. Thereafter, examination is done every 6 months until 5 years postoperatively. Then, every 6-12 months for the rest of the life.